Although Stevens-Johnson syndrome and toxic epidermal necrolysis were not seen in controlled clinical trials, there were occurrences in after market use of Trileptal.  Do you have any statistics regarding occurrences of SJS or TEN with the use of Trileptal? I wrote to the manufacturer (Norvartis I think) asking this same question, and they replied saying to have a healthcare representative contact them.

Thanks,
Jen

Dear Jen -- 
There's a sophisticated question (makes me wonder what event or worry lies behind it, of course...). Not having written my healthcare representative, I don't have those numbers either.  I haven't heard they're significantly different from Tegretol (carbamazepine, also from Novartis), because Novartis took care to point out the differences from Tegretol when Trileptal became available in the US, and a lower rash rate was not one of those differences (nor was it said to be higher).  Here's an article that might get you a ballpark number, or you could start from this recent review.  

Dr. Phelps


Published September, 2003